Merck

Targeted therapy is the most preferred option for cancer treatment and a number of new targets are being discovered which target cancer specific receptors, AKT being one of them. Protein kinase B (PKB), also known as AKT, belongs to serine/threonine protein kinase superfamily. AKT has been validated as a potential t...

NPPA slams pharma giants for overcharging The price regulator in the pharmaceutical industry, National Pharmaceutical Price Authority (NPPA) has discovered that the leading Pharma companies are overcharging customers for abundantly prevalent drugs in the market. NPPA has alleged that the listed 634 drugs are being s...

EC grants marketing authorisation for Takeda’s Ninlaro capsules The European Commission (EC) has granted conditional marketing authorisation for Takeda Pharmaceutical’s Ninlaro capsules. The oral proteasome inhibitor is indicated in combination with lenalidomide and dexamethasone for adult patients with multiple mye...

Merck provided substantial evidence of safety and effectiveness for the approval of bezlotoxumab in June 2016 to the FDA, and the administration’s Antimicrobial Drugs Advisory Committee voted 10 to 5 with 1 abstention to recommend its approval. In October 2016, bezlotoxumab commercialized as Zinplava, got approved b...

Merck is a leading science and technology company, and has many projects that are involved in research to find treatments for diseases that are hard to treat. Keeping in view with this agenda, Merck has announced that the new research that has been conducted from their marketed and pipeline compounds will be present...

Piramal buys another U.S. manufacturer operation India’s Piramal has decided to have a manufacturing operations based in the U.S., and has now bought another operation after it bought a sterile manufacturing operation last year. The company bought Midwestern-based CDMO for $42.95 million in cash, with an additional ...

The industry's 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche's Rituxan, Avastin and Herceptin franchises extending their lead at the top of this league table. With combined sales of around $21 billion, these three drugs alone accounted for approximately 56 percent of t...